Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
White Paper Declaration

PHAR price history

interval date selector

agregation type selector

Date

Change

Chg%

Open

Min.

Max.

2022-09-30

1.695

0.011

0.65

1.684

1.745

2022-09-30

1.72

0.024

1.42

1.696

1.673

1.736

2022-09-30

1.703

-0.081

-4.54

1.784

1.695

1.808

2022-09-30

1.764

0.059

3.46

1.705

1.695

1.766

2022-09-30

1.7

0.038

2.29

1.662

1.613

1.714

2022-09-30

1.666

-0.025

-1.48

1.691

1.663

1.744

2022-09-30

1.674

0.132

8.56

1.542

1.532

1.681

2022-09-30

1.508

0.022

1.48

1.486

1.453

1.512

2022-09-30

1.489

-0.003

-0.20

1.492

1.45

1.499

2022-09-30

1.514

-0.020

-1.30

1.534

1.497

1.536

2022-09-30

1.589

0.041

2.65

1.548

1.593

2022-09-30

1.554

-0.011

-0.70

1.565

1.53

1.591

2022-09-30

1.557

0.032

2.10

1.525

1.492

1.567

Trade Pharming Group N.V. - PHAR stock price

The Power Of Leverage

PHAR price history